Imaging Poliovirus Entry in Live Cells by Brandenburg, Boerries et al.
Imaging Poliovirus Entry in Live Cells
Boerries Brandenburg
1,2[, Lily Y. Lee
3[, Melike Lakadamyali
4, Michael J. Rust
4, Xiaowei Zhuang
1,2,4*, James M. Hogle
3*
1 Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts, United States of America, 2 Howard Hughes Medical Institute, Cambridge,
Massachusetts, United States of America, 3 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, United States
of America, 4 Department of Physics, Harvard University, Cambridge, Massachusetts, United States of America
Viruses initiate infection by transferring their genetic material across a cellular membrane and into the appropriate
compartment of the cell. The mechanisms by which animal viruses, especially nonenveloped viruses, deliver their
genomes are only poorly understood. This is due in part to technical difficulties involved in direct visualization of viral
gene delivery and to uncertainties in distinguishing productive and nonproductive pathways caused by the high
particle-to–plaque forming unit ratio of most animal viruses. Here, we combine an imaging assay that simultaneously
tracks the viral capsid and genome in live cells with an infectivity-based assay for RNA release to characterize the early
events in the poliovirus (PV) infection. Effects on RNA genome delivery from inhibitors of cell trafficking pathways
were probed systematically by both methods. Surprisingly, we observe that genome release by PV is highly efficient
and rapid, and thus does not limit the overall infectivity or the infection rate. The results define a pathway in which PV
binds to receptors on the cell surface and enters the cell by a clathrin-, caveolin-, flotillin-, and microtubule-
independent, but tyrosine kinase- and actin-dependent, endocytic mechanism. Immediately after the internalization of
the virus particle, genome release takes place from vesicles or tightly sealed membrane invaginations located within
100–200 nm of the plasma membrane. These results settle a long-lasting debate of whether PV directly breaks the
plasma membrane barrier or relies on endocytosis to deliver its genome into the cell. We expect this imaging assay to
be broadly applicable to the investigation of entry mechanisms for nonenveloped viruses.
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Introduction
As obligatory intracellular parasites with limited genetic
capacity, viruses have evolved to hijack intrinsic cellular
pathways to enter the cell and deliver their genomes to
speciﬁc cellular locations for replication. Therefore, mecha-
nistic understandings of viral entry may not only lead to new
therapies for combating viral infection, but also provide new
insights into fundamental cellular functions [1]. A number of
distinct strategies have been exploited for viral entry and
gene delivery. For enveloped viruses, protein-assisted fusion
of viral and cellular membranes provides a conceptually
simple mechanism for capsid or genome release into the
cytoplasm [2]. For nonenveloped viruses, the mechanism is
less well understood, but appears to rely upon viral capsid
proteins (VPs) to disrupt cellular membranes or to form
pores through them [3]. The cellular sites where genome
release occurs are unknown for most nonenveloped viruses.
Here, we chose poliovirus (PV) as a model system to study
entry and genome delivery by nonenveloped viruses. PV is a
picornavirus that causes human poliomyelitis and is closely
related to other important human viral pathogens, including
rhinoviruses, coxsackieviruses, echoviruses, and enteroviruses.
The virion is comprised of an icosahedral capsid, harboring a
positive-sensed single-stranded RNA (;7.5 kilobases) [4].
PV infection is initiated when the virus binds the poliovirus
receptor (PVR, or CD155) [5]. At physiological temperature,
the binding of multiple PVRs triggers an irreversible
conformational change in the native virion (160S particle),
resulting in the formation of an altered particle (135S) [6].
This conformational change results in externalization of
myristoylated capsid protein VP4 [6,7] and the N-terminus of
the capsid protein VP1 [8]. Both of the externalized peptides
then insert into membranes [8,9], allowing the virus particle
to anchor to the cellular membrane in a receptor-independ-
ent manner [8,10] and to form channels and pores in planar
membranes [9,11,12]. This has led to the suggestion that the
membrane-associated viral peptides facilitate translocation
of the viral genome across the plasma or vesicle membrane
and into the cytoplasm. Genome release results in the
formation of a stable empty particle (the 80S particle) [13].
The pathway by which PV enters cells is unclear. Early
studies using electron microscopy, cell fractionation, lyso-
trophic amines, and inhibitors of endocytosis suggested that
PV enters cells via clathrin-mediated endocytosis and that
viral uncoating depends on acidiﬁcation of early endosomes
[14–18]. In contrast, more-recent studies have demonstrated
that PV infection is not affected by expression of dominant
negative mutants of the protein dynamin (which is required
for maturation of clathrin-coated vesicles and caveolae) [19]
or by treatment with bafalomycin A1 (a speciﬁc inhibitor of
the vacuolar proton pump); but that entry is blocked by co-
administration of valinomycin, an ionophore that induces
potassium ion efﬂux, and concanamycin A, a vacuolar proton
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The conﬂicting results highlight several fundamental difﬁ-
culties associated with characterizing viral entry pathways: (1)
the high particle-to–plaque forming unit (pfu) ratio of animal
viruses (100:1 to 200:1 for PVs, and higher for many other
viruses) makes it difﬁcult to distinguish productive from
nonproductive pathways, (2) conventional biochemical and
visualization assays generally require a very high multiplicity
of infection (MOI), increasing the probability of sampling
nonproductive pathways, and (3) inhibitors of cell trafﬁcking
pathways (including small molecules, small interfering RNAs
[siRNAs], and dominant negative mutants) may have poorly
characterized secondary targets that affect events down-
stream of the entry process. Consequently, despite decades of
study, the PV cell entry pathway remains a mystery. Indeed,
even questions such as whether the virus directly releases its
genome across the plasma membrane or hijacks an endocytic
pathway to deliver the genome from an intracellular
organelle or vesicle remain unanswered.
In this work, we characterized the PV entry pathway by
combining live-cell imaging of infectious dual-labeled PV in
which the viral capsid and RNA were labeled with distinct
ﬂuorophores with biochemical assays that directly measure
RNA release. These assays were used to characterize early
events in infections initiated at a low MOI in the presence or
absence of inhibitors of cell trafﬁcking pathways. We found
that PV RNA release was a rapid and efﬁcient process that did
not limit the speciﬁc infectivity of the virus. After binding to
the cell, the virus particles were internalized in an actin-
dependent manner. The genome release took place only after
endocytosis, in vesicles very close (within 100–200 nm) to the
plasma membrane. The kinetics of RNA release in the
visualization assay and the biological assay were indistin-
guishable, and both assays demonstrated that RNA release
was energy-, actin-, and tyrosine kinase-dependent, but did
not require clathrin, caveolin, ﬂotillin, or microtubules.
Results
Capsid and Genome Dual-Labeled PV
Simultaneous visualization of viral capsid and genome
requires the identiﬁcation of distinct ﬂuorescent labels for
the capsid proteins and genome RNA that do not reduce the
speciﬁc infectivity of the virus. The capsid of puriﬁed PV can
be readily labeled with amine-reactive dyes (e.g., Cy5, Cy3,
and Alexa Fluor 633). Unfortunately, the RNA genome, once
incorporated into the virion, is not accessible to dye attach-
ment even when the dyes and virions are co-incubated at
temperatures permissive for capsid ‘‘breathing,’’ a phenom-
enon that has previously been shown to allow incorporation
of dyes such as Ribogreen into rhinoviruses [21,22]. We
therefore turned to a metabolic labeling strategy to incorpo-
rate dye-labeled RNA during the viral replication process. A
similar approach has been used to introduce neutral red (NR)
and acridine orange into virions [23,24], but these dyes are
unsuitable for imaging because they rapidly inactivate the
viral RNA upon illumination. More than 20 RNA-binding
dyes, including Ribogreen, RNA Select, and a series of Syto
dyes from Molecular Probes, were screened by the following
criteria: (1) the dye must be membrane permeable, (2) it must
be noncytotoxic, (3) it must be able to bind viral RNA at
sufﬁcient levels to allow single RNA visualization, (4) it must
not interfere with RNA incorporation into virions, and (5) it
must not reduce the speciﬁc infectivity of the virus. Only one
dye, Syto82 (excitationmax ¼ 541 nm, and emissionmax ¼ 571
nm), met all ﬁve criteria. Experiments with in vitro–tran-
scribed PV RNA showed that unfolding the RNA substantially
reduced the ﬂuorescent signal of Syto82 originally associated
with the RNA (unpublished data), suggesting that RNA
secondary structure is important for Syto82 binding, con-
sistent with the property of intercalating dyes. We chose Cy5
(excitationmax ¼ 649 nm, and emissionmax ¼ 670 nm) as the
complementary capsid label.
The protocols for labeling the capsid and RNA were
optimized such that both dyes were incorporated to yield the
highest level of ﬂuorescent signal without appreciably
affecting PV infectivity (Figures 1A and S1). Under these
conditions, the average number of Cy5 dye molecules per PV
particle was estimated to be 40–50. We thus expect nearly
100% of the virus particles to be Cy5 positive. Consistent with
this hypothesis, nearly 100% of the virions with Syto82 signal
also exhibited Cy5 signal. However, 55%–65% of the Cy5-
positive virions showed Syto82 signal. The remaining virions
presumably did not contain a sufﬁcient amount of Syto82 for
single-particle detection.
Genome RNA Release of PV Is Rapid and Efficient
The highly efﬁcient labeling of viral capsid and RNA
allowed us to monitor the RNA release in live cells at the
single-virion level. To this end, we infected human cervical
carcinoma-derived cells (HeLa S3) with the dual-labeled virus
at a low MOI (1 pfu/cell), which allows us to discern individual
virus particles. About 300–400 PV particles were observed
bound per cell. After incubation with cells at 37 8C, the bound
virus particles lose their RNA signal over time (Figure 1B). A
time course of this process can be directly visualized from
images of the same cell taken at different time points (Figure
S2A and S2B). The same experiment conducted at lower
temperature (24 8C) showed little RNA signal loss (Figure S2C
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Author Summary
During travel between hosts, the genome of a virus is well protected
by the viral capsid and/or envelope. After binding specifically to
target cells, the virus particles enter cells by hijacking cell trafficking
pathways and then deliver the viral genome into the appropriate
compartment of the cell where it directs the production of progeny
virus particles. How nonenveloped viruses, such as poliovirus, enter
target cells is not well understood. Here, we produced fully
infectious poliovirus with both genome and capsid specifically
labeled by fluorescent dyes. We could then use real-time fluorescent
microscopy to follow single virus particles during infection, to define
how they enter cells and to determine when and where in the cell
the genome gets released. We have complemented the microscopic
studies with virological assays, which demonstrate that the path-
ways observed by microscopy are productive. We show that
poliovirus enters live cells in a process that requires energy, an
intact actin cytoskeleton, and cell signaling pathways, but does not
depend on the well-known markers of endocytic pathways. We
show that after internalization, the genome release is surprisingly
efficient and occurs from vesicles that are very close to the cell
surface. Our experiments offer new insights into the early steps of
poliovirus infection, and describe methods that can be used for a
wide variety of other viruses.and S2D), suggesting that the ﬂuorescence loss was not due to
photobleaching of the RNA label, but rather due to RNA
release. In this experiment, short exposure-time images (500
ms) were recorded only every few minutes to avoid extensive
photobleaching of the Syto82 dye and photodamage of the
dye-labeled RNA. In order to ensure that any potential effect
of photodamage was excluded, we also adopted an alternative
imaging procedure and changed the imaging area after each
time point, such that no cells were imaged more than once or
ever exposed to excitation prior to imaging. A similar RNA
release kinetics curve was obtained (Figure 1C). The viruses
began to lose their RNA signal after an initial lag of about 10
min, and the fraction of Cy5-positive particles containing
Syto82 signal showed a steep descent between 10 and 30 min.
As a negative control, we used the Janssen drug R78206 [25],
which binds speciﬁcally to PV capsids and prevents the
receptor-induced conformational change and subsequent
RNA release. In the presence of R78206, the fraction of
Cy5-positive particles containing Syto82 signal remained
constant throughout the experiment (Figure 1C), suggesting
that the loss of RNA label is indeed due to the release of RNA
from the virus particles. Interestingly, the loss of Syto82 signal
from the Cy5-positive capsids was not accompanied by the
appearance of single-colored Syto82 spots elsewhere, whereas
the binding of Syto82 to in vitro–transcribed PV RNA at
physiological salt concentrations was found to be stable for
several hours. We thus propose that RNA release requires
disruption of the RNA secondary structure leading to the
release of the RNA dye upon externalization.
Surprisingly, RNA release was highly efﬁcient. At the outset
of infection, roughly 60% of the Cy5-labeled virus contained
the RNA label. By 60 min postinfection (p.i.), the percentage
was reduced to 10%–15% (Figure 1C). RNA release in HeLa
cells occurred with a t1/2 of 22 6 3 min. We also analyzed the
RNA release kinetics in human kidney-derived cells (Hek 293)
and human neuroblastoma cells (SH-SY5Y). Although the
kinetics of release was slower in Hek 293 and in SH-SY5Y cells,
RNA release was efﬁcient in all three cell types (Figure 1D).
To further verify the results of the imaging assay, we
performed an infection-based assay for RNA release using
Figure 1. Rapid and Efficient RNA Release of PV
(A) Dual-labeled PV genomic RNA, labeled with Syto 82 (green) colocalizes with the Cy5 labeling of the viral capsid (red). Scale bar indicates 5 lm.
(B) Imaging of RNA release in live HeLa cells at the single virus particle level. Cells infected with dual-labeled PV and imaged 10 min and 60 min p.i..
Scale bar indicates 10 lm.
(C) PV RNA release kinetics in HeLa cells. The cells were infected with PV at MOI¼1. The fraction of Cy5-positive particles containing Syto82 signal was
detected and counted at different time points postinfection. In contrast to the R78206 negative control (R78206 specifically binds PV capsid and inhibits
conformational change and RNA release), untreated dual-labeled PV releases RNA efficiently.
(D) RNA release could be observed in several cell types with only moderate kinetics delays.
(E) RNA release kinetics measured in the NR assay. At various time points, the cells infected with NR-labeled viruses were exposed to white light,
inducing NR crosslinking of the viral RNA only while the dye and RNA are constrained within the virus particle. Upon RNA release, the dye and RNA are
no longer constrained, and the infection becomes insensitive to irradiation. The plot shows the titer numbers measured in cells exposed to light at
various time points postinfection.
doi:10.1371/journal.pbio.0050183.g001
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Polio EntryNR-containing virus. NR is readily incorporated into virions
grown in cells containing the dye. It has been shown that
exposure to light can cause NR dye to crosslink viral RNA
when both are contained within the capsid, rendering the
virus particle noninfectious (Figure S1) [23,24]. Upon RNA
release, the dye is detached from the RNA and the infection
becomes insensitive to irradiation. This assay has been used
to probe the effects of mutations and drugs on the kinetics of
RNA release [16,26]. The kinetics of RNA release as measured
by this assay (t1/2 between of 27 6 3 min) closely mirrored the
kinetics of RNA release as measured by the visualization assay
(Figure 1E, see also [9]), supporting that the RNA release
visualized by our imaging assay is relevant to infection.
Genome Release Occurs after Virus Internalization from
Vesicles near the Plasma Membrane
Confocal images of cells infected with dual-labeled virus at
various times p.i. provided us with the ﬁrst glimpse of the PV
RNA release sites. At an early point (5 min p.i.) before any
substantial RNA release took place, nearly all of the labeled
viruses remained close to the cell surface. Only at later time
points (20–50 min p.i.) was there an accumulation of virus
particles in the inner part of the cell body. These particles
were nearly exclusively singly labeled, containing only the
capsid (Cy5), but not the RNA (Syto82) label, whereas a
substantial fraction of the particles near the cell surface
remained both capsid and RNA positive (Figure 2A). These
Figure 2. PV RNA Release Occurs near the Cell Surface
(A) Live HeLa cells at different times postinfection with dual-labeled PV (MOI¼2–3). During the infection, the number of capsids (red) observed inside
the cell is increasing. Colocalization with the RNA (green) is observed primarily near the cell surface and rarely seen deep inside the cell. Scale bar
indicates 10 lm. DIC, differential interference contrast.
(B)ByusingTIRFmicroscopy,itispossibletoinvestigateRNAreleasekineticswithinthe100–200nmoftheevanescentfieldattheadherentsurfaceofthecell.
(C) PV RNA releases observed under TIRF imaging condition.
doi:10.1371/journal.pbio.0050183.g002
PLoS Biology | www.plosbiology.org July 2007 | Volume 5 | Issue 7 | e183 1546
Polio Entryimages were taken at a higher MOI (2–3 pfu/cell) for visual
demonstration, but were not used for single-virus counting
analysis. Similar results were observed at a lower MOI at
which individual virus particles are discernable, suggesting
that RNA release primarily took place near the cell surface;
and afterwards, empty capsids were transported towards
more-interior regions of the cell.
Immediately after inoculation, PV particles were ﬁrst
observed at the top surface of the cell and began to appear
at the bottom adhering surface only after a short delay of 1–3
min. Previous studies on polarized cells have shown that PV is
able to enter via both the apical and the basolateral surface
[27]. We therefore analyzed the z-scans to separately assess the
rates of RNA release from the top and bottom surfaces of live
cells. Both surfaces exhibited similar kinetics of RNA release
(unpublished data). This allowed us to image genome release
from the adherent cell surface using total internal reﬂection
ﬂuorescence (TIRF) microscopy (Figure 2B). The evanescent
wave produced by total internal reﬂection generates an
illumination ﬁeld of only 100–200 nm deep from the
adhering cell surface, allowing us to precisely determine the
proximity of RNA release sites to the plasma membrane. In
these experiments, a low MOI (1 pfu/cell) was used to allow
virus particle counting. We found that RNA was efﬁciently
released within the TIR illumination ﬁeld in both experi-
ments in which the same cell was repetitively imaged (Figure
S2C) or in which the imaging area was changed after each
time point (Figure 2C), indicating that genome release was
taking place within 100–200 nm of the cell surface. As a
control, we conducted the same imaging assay at 12 8C, a
temperature at which infection does not occur [28]. The
fraction of particles containing the RNA label remained
constant throughout the experiment (Figure 2C), indicating
the genome release is temperature dependent.
In order to determine whether RNA release was taking
place at the plasma membrane or from internalized vesicles
close to the cell surface, we performed an experiment in
which the capsid was labeled with a pH-sensitive dye,
CypHer5, which is brightly ﬂuorescent at neutral and acidic
pH values (pH   7) but becomes essentially nonﬂuorescent at
pH   9. Cells infected with dual-labeled virus were pulsed
with pH 9.5 media at various time points (Figure 3A). Because
a living cell is able to buffer its internal pH, only the
population of PV outside the cell would be sensitive to
changes in the extracellular pH (Figure 3B). The kinetics of
RNA release was similar to those observed previously with
Cy5-labeled viruses in neutral media (Figure 3C). The
percentage of input virus particles sensitive to external pH
change decreased as a function of time, indicating the
internalization of the virus particles. The measured internal-
ization kinetics closely mirrored the RNA release kinetics
(Figure 3C). These results indicate that the RNA release
occurred roughly at the same time the virus particles were
internalized. Remarkably, RNA release was not observed
among the virus particles that remained on the cell surface
and sensitive to external pH change (Figure 3C, red curve),
indicating that RNA release only occurred after internal-
ization or at least after the virion become sheltered from the
extracellular medium. Taken together, these results suggest
that PV must ﬁrst enter the cell before releasing its genome
and that the genome release occurs quickly afterward, within
a distance of 100–200 nm of the plasma membrane.
An Infectivity-Based Assay for RNA Release
Whereas imaging labeled viruses in living cells provides a
powerful assay to probe the kinetics and sites of viral genome
release, this type of assay also has a signiﬁcant limitation—it
doesnotdirectlyshowwhethertheobservedRNAreleaseleads
to infection. In order to establish the biological signiﬁcance of
Figure 3. PV RNA Release Occurs after Virus Internalization
The pH-sensitive CypHer5 PV capsid labeling allows distinction between
the population of viruses outside versus inside the cell.
(A) Live cells were pulsed during the infection with pH 9.5 medium.
(B) CypHer5 becomes nonfluorescent at pH 9.5, resulting in the
disappearance of capsid signals outside the cell (black capsid) during
the pulse. Viruses that have already entered the cell are protected by the




to release RNA. Capsids on the surface do not release their RNA (red).
doi:10.1371/journal.pbio.0050183.g003
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neutral red–dependent infectious center (NRIC) assay [16] to
speciﬁcallytargetearlyinfectionstepsleadingtotheviralRNA
release. In the reﬁned NRIC assay (Figure 4A), HeLa cells were
pretreatedwithagiveninhibitorfor1hpriortoinfectionwith
NR-labeled PV at an MOI of one. At 30 min p.i., the cells were
exposed to light to inactivate viruses that had not yet released
RNA. The drugs were then removed, and the inoculated cells
were then seeded onto a fresh layer of cells in the absence of
inhibitor, and the percentage of cells infected was determined
by plaque assay. In a parallel assay, the light illumination step
was omitted to control for irreversible effects of the inhibitor
on the cell or the virus.
In order to conﬁrm that the assay is able to distinguish
between the effect of drugs on RNA release and late stages of
infection, we used the assay to assess the effect of two drugs:
the capsid-binding drug R78206, a drug known to block
conformational changes and RNA release (Figure 1C) [25];
and brefeldin A, a drug that disrupts endoplasmic reticulum
to Golgi trafﬁcking that has been shown to block PV RNA
replication late in infection, but has no effect on early events
[29]. As expected, the PV-speciﬁc inhibitor R78206 caused
severe and irreversible reduction in titer in the NRIC assay
(Figure 4B). Consistent with earlier ﬁndings, brefeldin A had
a pronounced effect on viral replication in a conventional
plaque assay when present throughout infection, but had no
effect on infection in the NRIC assay or in the plaque assay if
the drug was washed out. We combined the imaging assay and
NRIC assay to probe the effects of a panel of inhibitors of cell
trafﬁcking pathways to gain additional insights into the
mechanism of PV entry, as discussed below.
The PV Genome Release Is ATP Dependent
Endocytosis is an energy-dependent process. The observa-
tion that RNA release only occurs after internalization of the
virus particles suggests that the release of PV RNA would be
energy dependent. To test this hypothesis, we depleted
cellular ATP by pretreating the cells with sodium azide and
2-deoxyglucose. Depletion was conﬁrmed by the absence of
mitochondrial staining with rhodamine 123 [30]. As expected,
PV was unable to release its RNA in ATP-depleted cells
(Figure 5A). Consistent with this result, the RNA release also
did not proceed at 12 8C, a temperature at which endocytosis
is not permitted. Using the NRIC assay, we observed a severe
reduction in the percentage of cells infected when ATP was
depleted using sodium azide and 2-deoxyglucose (Figure 5B),
but the reduction was not observed when the illumination
step was omitted. These observations demonstrate that the
steps leading to productive RNA release are ATP dependent.
PV Entry Depends on Actin, but Not Microtubules
Many endocytosis processes are actin dependent [31]. To
further test the idea that PV genome release takes place after
endocytosis of the virus particle, we sought to test the actin
dependence of RNA release. To this end, we treated the cells
with cytochalasin D (Cyto-D), a drug that causes actin
depolymerization. As visualized in the live-cell imaging assay,
virus particles still bound in similar quantities to the treated
cells as to the untreated cells, suggesting that Cyto-D
treatment did not affect PV–PVR interactions. To test
whether the internalization of the virus particles were
inhibited by Cyto-D, we again exploited our CypHer 5–
labeled PV (Figure 6A). In contrast to untreated cells in which
the virus label rapidly became insensitive to extracellular pH
change, the great majority of virus particles added to Cyto-D–
treated cells remained sensitive to the pH change throughout
the experiment (60 min), indicating that the internalization
of PV is indeed inhibited by actin disruption.
Remarkably, the fraction of virus particles containing
Syto82 remained constant throughout the entire course of
the experiment (60 min), indicating that genome release was
severely inhibited by disrupting actin cytoskeleton (Figure 6A
and 6B). Similarly, we observed a signiﬁcant decrease in the
titers measured in Cyto-D–treated cells using the NRIC assay
as compared to control cells (Figure 6C). These results
indicate that productive RNA release is actin dependent,
Figure 4. The Neutral Red Infectious Center Assay
(A) Schematic for the NRIC assay. Cells were pretreated with an inhibitor
for 1 h prior to infection in the dark with NR PV. Infection was initiated by
warming to 37 8C. In order to probe for inhibitor effects only during the
early steps of infection, the cells were exposed to white light at 30 min
p.i. to inactivate intact viruses, the inhibitor was removed, and the cells
were trypsinized. The detached cells were used to infect a fresh
monolayer of HeLa cells in the absence of inhibitor, and the plaques
were counted at 2 d p.i..
(B) Brefeldin A is known to inhibit later stages of PV infection and was
used to demonstrate the ability of the NRIC assay to exclusively show
inhibitor effects during the early stage of PV infection. In contrast to a
normal plaque assay, Brefeldin A in the NRIC assay has no effect on the
infection. R78206 was used as a positive control that irreversible binds
and inactivates the PV capsid. Triple asterisks (***) indicate p , 0.001.
doi:10.1371/journal.pbio.0050183.g004
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internationalization of the viral particle.
In contrast, RNA release was shown by both live-cell
imaging and NRIC assay to be unaffected by nocodazole,
which inhibits microtubule-dependent transport in cells
(Figure 6B and 6C). The lack of microtubule dependence in
both assays suggests that the productive RNA release is
unlikely to be dependent on the acidic environment of late
endosomes and lysosomes. Consistent with this conclusion,
treatment with baﬁlomycin A1, a vacuolar proton ATPase
inhibitor that prevents endosome acidiﬁcation, had no effect
on PV infectivity (Figure 6C). The lack of dependence of RNA
release on microtubules and acidiﬁcation of endosomes is
consistent with previously published results [18,32,33]. After
RNA release, empty capsids almost exclusively labeled with
Cy5 only were found to rapidly move in a microtubule-
dependent manner towards the cell center. This behavior
should thus be irrelevant to infection, and may suggest that
the empty capsids are transported to compartments with a
degradative environment, such as late endosomes and
lysosomes. Trafﬁcking of endocytic ligands to these organelles
is typically microtubule dependent [34].
PV Infection Does Not Require Clathrin, Caveolin, Flotillin,
or Macropinocytosis, but Depends on Tyrosine Kinases
Having established that the RNA release occurs only after
internalization, a natural question arises as to what endocytic
mechanism is exploited by PV. A number of endocytic portals
were used by animal viruses to gain entry into the cell,
including clathrin-mediated endocytosis, caveolin-mediated
endocytosis, clathrin- and caveolin-independent pathways,
andmacropinocytosis [1,35]. To characterizewhich pathway(s)
may be used by PV, we used the NRIC assay to test the effect of
previously established endocytic inhibitors (Figure 7).
Although chlorpromazine is commonly used to inhibit
clathrin-mediated endocytosis, this drug also elicits other
secondary effects on the cell, including inhibition of voltage-
gated potassium channels in neuronal cells, and inhibition of
lysosomal and cytosolic phospholipases [36,37]. In the NRIC
assay, chlorpromazine treatment resulted in similar levels of
reduction in infection in both the illuminated cells and
nonilluminated controls, suggesting that these or other side
effects of the drug dominate the decrease in titer (unpub-
lished data). To speciﬁcally inhibit clathrin-mediated endo-
cytosis, we used siRNA to knockdown the expression level of
clathrin heavy chain (CLTC) or that of the l1 subunit of AP2
complex. Both siRNAs have been previously used to inhibit
clathrin-mediated endocytosis [38]. Knockdown was con-
ﬁrmed by Western blot analysis (Figure 7A). As a positive
control, we conﬁrmed that the uptake of ﬂuorescently labeled
transferrin was blocked in the CLTC siRNA-transfected cells,
but not in cells transfected with noncoding siRNA (Figure
7B). In contrast to the marked effect on transferrin uptake,
the knockdown of CHC or AP2 had no signiﬁcant effect on
PV infection (Figure 7C), suggesting the entry of PV does not
require clathrin-mediated endocytosis. Consistent with this
conclusion, imaging of PV in live cells expressing ﬂuorescent
clathrin fusion proteins [39] did not reveal signiﬁcant
colocalization of PV with clathrin-coated pits prior to PV
entry (unpublished data).
A number of viral entry pathways, including classical
caveolin-mediated endocytosis, were reported to be depend-
ent on cholesterol-rich domains or rafts [40,41]. Sensitivity to
drugs that deplete cholesterol either by removing it from
membranes (e.g., methyl-b-cyclodextrin [MbCD]) or by inhib-
iting cholesterol synthesis (nystatin and progesterone), or
drugs that bind cholesterol and interfere with raft formation
(ﬁlipin) have therefore often been used as surrogate markers
for caveolin-dependent endocytic pathways. Among these
drugs, ﬁlipin is arguably less prone to downstream effects
from bulk depletion of cholesterol. We thus tested the
involvement of caveolin-mediated endocytosis using ﬁlipin.
Our NRIC assay showed that ﬁlipin has no effect on PV
infection at a concentration of 2 or 20 lg/ml (Figure 7C),
concentrations that efﬁciently block the entry of ﬂuorescently
labeled cholera toxin [39,42]. These results suggest that PV
enter HeLa cells through a caveolin-independent pathway.
We have also tested the effects of MbCD (Figure 7C), nystatin,
and progesterone (unpublished data). All of these drugs
substantially reduced PV infectivity in both illuminated
samples and the nonilluminated controls, suggesting irrever-
sible adverse effect by these drugs on the cells, unrelated to
Figure 5. PV Entry Is Temperature and Energy Dependent
(A) The single-virus imaging assay shows that PV RNA release does not
occur at nonphysiological temperatures (12 8C) and depends on the
presence of cellular ATP that can be depleted by treating the cells with
sodium azide (NaAz) and deoxyglucose.
(B) The ATP dependence of PV RNA release shown in the NRIC assay.
Triple asterisks (***) indicate p , 0.001.
doi:10.1371/journal.pbio.0050183.g005
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by Liu et al [43], and explains why earlier studies using
cholesterol-depleting MbCD show inhibited PV infection [41].
Combining clathrin siRNA and ﬁlipin to simultaneously
inhibit clathrin-mediated endocytosis and caveolin-mediated
endocytosis also had no signiﬁcant effect on PV entry,
suggesting that PV enter HeLa cells via a clathrin- and
caveolin-independent pathway. Recently, ﬂotillin-1 was iden-
tiﬁedasamarkerproteinforasubsetofclathrin-andcaveolin-
independentpathways[42,44].Knockingdownﬂotillin-1witha
speciﬁc siRNA (Figure 7A) showed no effect on the PV
infection,butthesameknockdownprocedureinhibitedseveral
cationic ligands that we have shown to enter cells through a
clathrin- and caveolin-independent pathway [42], suggesting
that PV entry also does not require ﬂotillin-1 (Figure 7C).
Although macropinocytosis has not previously been im-
plicated as a signiﬁcant pathway in PV entry [45], we also
tested the effects of amiloride, a drug that interferes with
macropinocytosis by blocking sodium channels. At concen-
trations (200 lM) that block the uptake of ﬂuorescently
labeled dextran though macropinocytosis, amiloride did not
affect the ability of PV to infect cells (Figure 7C).
Tyrosine kinases are often involved in cortical actin
remodeling, endocytosis, intracellular trafﬁcking, and various
steps of viral infection [46–50]. We therefore tested the effect
of tyrosine kinase inhibitors on polio entry by the NRIC assay.
A strong inhibitory effect on PV infection was observed with
genistein, a well-known tyrosine kinase inhibitor with broad
speciﬁcity, but not with genistin, an inactive analog often
used to screen out nonspeciﬁc effects (Figure 8). However,
tests with inhibitors that more narrowly impact subfamilies of
tyrosine kinase, including PP2 (an Src family inhibitor with
high afﬁnity for p56 and Hck), SU6656 (an inhibitor of src
family kinases with high afﬁnity for Src), and wiskostatin (an
inhibitor of the NWASP, Arf2/3 pathway), exhibited at most a
moderate effect on PV infection. Thus, the speciﬁc tyrosine
kinase(s) involved remain to be identiﬁed.
Discussion
The extracellular forms of viruses face formidable chal-
lenges. The virion itself must be sufﬁciently stable to protect
the viral genome during the passage from host to host and
cell to cell, and yet, upon reaching the target cell and
encountering the appropriate trigger, the virion must initiate
programmed steps that result in the release of the viral
genome into the appropriate compartment of the cell. For
nonenveloped viruses, the conceptually simple mechanism of
membrane fusion is not an option. Instead, they must provide
the machinery required to translocate either a nucleoprotein
complex or, minimally, the viral genome across a cell
membrane. Although some of the machinery required to
deliver the viral genome must be supplied by the virus itself, it
Figure 6. PV Entry Is Actin Dependent
(A) Actin-cytoskeleton is required for PV internalization and RNA release.
Cells were pretreated with an actin-disrupting drug, Cyto-D. By briefly
changing the pH in the medium to pH 9.5, signals of nearly all of the pH-
sensitive CypHer5-labeled viral capsids disappeared at 60 min p.i.,
indicating that the virus particles were still outside of the cells. The RNA
label (Syto82, green) was also detectable in nearly all of the virus
particles, indicating no RNA release in these particles. In contrast, in
untreated cells, the majority of viruses have entered the cell and released
their RNA genome by 60 min p.i. (Figure 3C). Scale bar indicates 10 lm.
(B) The single-virus imaging assay shows that PV RNA release is inhibited
by Cyto-D, but not by the microtubule-depolymerizing drug, nocodazole.
(C) Similarly, RNA release is inhibited by Cyto-D, but not by nocodazole
or bafalomycin A1 (which inhibit vacuolar proton pump and thus inhibit
endosome acidification) in the NRIC assay. Triple asterisks (***) indicate
p , 0.001.
doi:10.1371/journal.pbio.0050183.g006
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genomes, that most viruses hijack cellular pathways in order
to initiate infection. The characterization of the cell entry
pathways for nonenveloped viruses has been challenging due
to the difﬁculties associated with direct visualization of the
viral gene-delivery process, making it hard to determine
exactly when, where, and how the viral genome is released.
The situation is further complicated by a number of factors,
including the high particle-to-pfu ratio of most animal
viruses, which makes it impossible for visualization methods
and most biochemical methods to distinguish productive and
nonproductive pathways. As a result, the entry pathways of
most nonenveloped viruses remain poorly understood. This is
true even for viruses like PV, which have been the subject of
decades of research, and have long been thought of as models
for understanding viral–host interactions.
To overcome the above problems, we developed assays that
focus more directly on productive pathways. Toward this end,
we established a protocol for labeling viral RNA by growing
virus particles in the presence of cell-permeable nucleic acid–
binding dyes. The dye labels did not inhibit viral infectivity
but provided sufﬁciently bright signal for single viral RNA
imaging in live cells. The simultaneous labeling of viral
genome and capsid allowed us to follow individual viral
capsids together with their genomic RNA so as to precisely
Figure 7. Endocytosis of PV Is Independent of Clathrin, Caveolin, Flotillin, and Macropinocytosis
(A) The knockdown effect of siRNA against the clathrin heavy chain (siCLTC), the l1 subunit of the adaptor protein 2 (siAP2l1) and flotillin-1 (siFlotillin)
is shown by Western blot analysis.
(B) As a control, the uptake of Alexa Fluor 633–labeled transferrin was blocked in cells transfected with the CLTC siRNA (right) but not with noncoding
siRNA (left). Fluorescent transferrin was incubated with the HeLa cells for 40 min. Transferrin molecules remaining on the cell surface were removed by
an acid wash before imaging.
(C) Effect of siRNAs and small-molecule inhibitors on PV entry measured by using the NRIC assay. nsiRNA, noncoding siRNA.
doi:10.1371/journal.pbio.0050183.g007
Figure 8. Endocytosis of PV Is Tyrosine Kinase Dependent
Effect of various tyrosine kinase inhibitors on PV entry measured by
using the NRIC assay. A single asterisk (*) indicates p , 0.05; triple
asterisks (***) indicate p , 0.001.
doi:10.1371/journal.pbio.0050183.g008
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capsid (Figure 1). To complement this imaging approach, we
also reﬁned a NRIC assay to identify inhibitors that perturb
early infection steps leading to RNA release (Figure 4). We
coupled these two assays to address the PV entry mechanism
and to systematically screen the effect of small-molecule
inhibitors on PV infection. The complete correspondence of
the RNA release kinetics and effects of inhibitors in the two
assays provide compelling evidence that the pathways
elucidated in the visualization assay are biologically relevant.
Productive release of the viral genome has been previously
suggested as a major factor limiting the efﬁciency of infection
[45],butthemodelhasnotbeenrigorouslyprovedordisproved
due to the lack of suitable technology. Remarkably, we have
observed rapid and highly efﬁcient RNA release (Figures 1 and
S2). The close correspondence of the kinetics of RNA release
and the effects of inhibitors in the visualization and infectivity
assays (Figures 1, 5, and 6) suggest that the observed RNA
releaseisonthepathwayleadingtoinfection.Thisimpliesthat
the high particle-to-pfu ratio of PV results from steps after
genomerelease,possiblyincludingdegradationofviralRNAby
cellular RNases, inefﬁcient initiation of the ﬁrst round(s) of
translationofviralRNA(whichisuncappedandrequiresIRES-
dependent initiation) [4], or inefﬁcient assembly of the input
RNA into replication complexes.
We have shown that PV must enter the cell ﬁrst before the
RNAreleasecantakeplace.Therequirementofinternalization
is not only suggestedby the observation that the virus particles
remainingonthecellsurfacedidnotreleasetheirRNA(Figure
3), but also supported by the observed dependence of RNA
releaseandsubsequentinfectionontemperature,energy,actin
cytoskeleton, and tyrosine kinases (Figures 5–8). It is formally
possible that complete vesiculation is not required and that
RNA release takes place in a deep invagination inaccessible to
pH change in the extracellular medium. However, we do not
favor this latter model as this requires a sufﬁciently tight
restriction of the invagination neck to block passage of such
miniscule ions as hydrated protons and hydroxyl ions.
Remarkably, RNA release was found to occur almost
immediately following internalization of the virus particles
extremely close to the cell surface, in vesicles that were
located within 100–200 nm of the plasma membrane (Figure
2C). Whereas the site of RNA release was more precisely
determined for the adhering surface of the cell by TIRF, we
showed, using confocal microscopy, that RNA release took
place close to either the top (apical) or the bottom (attached)
surface of cells with similar kinetics (Figure 2A). Inhibitors
that disrupt actin cytoskeleton, deplete ATP, or inhibit
tyrosine kinases totally block infection from both surfaces
(Figures 5–8). Thus, the entry pathways from the two surfaces
of nonpolarized cells are most likely similar, if not identical.
The demonstration that genome release takes place from
vesicles very near the cell surface is consistent with previous
observations that endocytic acidiﬁcation and intact micro-
tubules are not required for PV infection [32,33]. Indeed, we
have conﬁrmed that neither raising endocytic pH nor
disrupting microtubules inhibits either RNA release or
infection (Figure 6). Interestingly, shortly after RNA release,
the empty capsids were observed to move rapidly along
microtubules. However, this transport behavior is unlikely to
be relevant to PV infection. Our results challenge previous
thoughts that PV RNA release may occur at the plasma
membrane or near the nucleus [45]. They also raise the
question of what triggers RNA release from the vesicles near
the plasma membrane. One potential candidate arises from
the curvature of the vesicles enveloping the viral particles,
which may allow additional copies of the N-terminus of VP1
to be inserted into the vesicle membrane or allow more
intimate association of the virus particles with the membrane,
generating mechanical forces that trigger RNA release. It is
also possible that internalization results in the recruitment of
cellular factors that facilitate RNA release and translocation
across the vesicle membrane. Using well-characterized endo-
cytic inhibitors, we demonstrated that the PV internalization
into HeLa cells does not require clathrin- or caveolin-
mediated endocytosis, but depends on yet unidentiﬁed
tyrosine kinase(s) (Figures 7 and 8). This is consistent with
earlier observations that a dominant negative mutant for
dynamin, a small GTPase involved in both clathrin- and
caveolin-mediated endocytosis, does not block the entry of
PV [19]. Therefore, although PV particles have been observed
in clathrin-coated pits in ﬁxed cells, this represents either a
nonproductive or a nonessential pathway. The entry behavior
of PV appears to be distinct from other picornaviruses: Foot-
and-mouth disease virus enters cell via clathrin-mediated
endocytosis and takes advantage of the acidic milieu of
endosomes to release genome [51], whereas echovirus 1 enters
cells using caveolin-mediated endocytosis and apparently
uncoats from the caveosome [52], and Coxsackievirus B3
enters polarized epithelial cells via caveolae and apparently
releases its viral genome from the endoplasmic reticulum
[49]. Diversity suggests that viruses in the family may be
rather promiscuous in their choice of pathways, and suggests
a possibility that viral entry mechanisms may be for a given
virus dependent on the type of cell being infected.
Taken together, the results of this study suggest the
following model for viral entry and genome release (Figure 9):
Figure 9. Model of PV Entry
After binding to cell-surface receptors, PV (160S) undergoes conforma-
tional changes of the capsid to the 135S form. The 135S particles are
then internalized by a clathrin- and caveolin-independent, but actin-
and tyrosine kinase-dependent, mechanism. The release of the viral
genome takes place only after internalization from an endocytotic
compartment localized within 100–200 nm of the plasma membrane.
Upon release of the RNA genome, the empty capsid (80S) is transported
away along microtubules.
doi:10.1371/journal.pbio.0050183.g009
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a clathrin-, caveolin-, and ﬂotillin-independent, but actin- and
tyrosine kinase-dependent, pathway. After internalization
(and only after internalization), the virus releases its RNA
rapidly from vesicles that are located within 100–200 nm of
the plasma membrane without requiring endocytic acid-
iﬁcation or microtubule-dependent transport. Our results
have settled the long-lasting debate of whether PV directly
breaks the plasma membrane barrier or relies on endocytosis
to deliver its genome into the cell. These results have also
opened interesting questions for this important virus that
await further investigation, including what characteristic of
these endocytic vesicles near the plasma membrane triggers
RNA release; and after release near the cell surface, how is the
released RNA transported to replication sites.
Materials and Methods
Cells and media. Adherent HeLa (S3), Hek 293, and SH-SY5Y cells
were maintained in a 5% CO2 environment at 37 8C in Dulbecco’s
modiﬁed Eagle medium (DMEM; Invitrogen, http://www.invitrogen.
com) supplemented with 10% fetal bovine serum, 1 mM nones-
sential amino acids, 2.5 mM glutamine, and antibiotics (25 U/ml
penicillin and 25 lg/ml streptomycin). Suspension cultures of HeLa
(S3) cells were maintained in Joklik’s minimal essential medium as
previously described [54].
Preparation of labeled PV. PV serotype 1, Mahoney strain, was
grown in suspension cultures of HeLa cells as previously described
[53,54]. To introduce the RNA dye into the virion, Syto 82 (Molecular
Probes, http://probes.invitrogen.com) was added to the infected cell
culture at 2 h p.i. at a ﬁnal concentration of 25 lM. Other RNA-
binding dyes tested (acridine orange, RiboGreen, RNA Select, and
Syto: 80, 81, 83, 85, 11, 12, 13, 14, 15, 16, 17, 59, 61, 63, and 64) did not
meet the ﬁve-criteria list in the main text and thus not were suitable
for the single-virus tracking experiments. To prepare NR-labeled
virus, cells were infected in the presence of 10 lg/ml NR. Infected
cells were harvested by centrifugation at 5.5–6 h p.i. and virus was
released by freeze-thawing the cell pellet twice. Cell debris was
removed by low-speed centrifugation, and virus was puriﬁed with a
CsCl density gradient as previously described [53]. For NR labeling,
the viruses were infected and puriﬁed in the dark. For labeling the
capsid with Cy5 or the pH-sensitive CypHer5 (GE Healthcare, http://
www.gehealthcare.com/usen/index.html), puriﬁed virus was incubated
with the amine-reactive dye in a carbonate buffer (pH 9.3) at 22 8C
and gently rocked for 1 h. Unbound dye was removed via buffer
exchange into 50 mM Hepes buffer (pH 7.4, 145 mM NaCl) using gel
ﬁltration columns (Nap5; GE Healthcare). Virus titers were deter-
mined using plaque assays on adherent HeLa (S3) cells [54].
Live-cell ﬂuorescence microscopy. Cells, cultured in glass-bottom
dishes (MatTek, http://www.mattek.com), were washed twice with PBS,
and PV was added to cells at 37 8C. After 5 min of incubation, the
unbound viruses were removed and replaced by fresh phenol red–free
DMEM (Invitrogen) containing 1% glucose, 50 mM Hepes, an oxygen-
scavenging system (glucose oxidase, 0.2 mg/ml [Sigma, http://www.
sigmaaldrich.com] and catalase, 1 lg/ml [Roche Diagnostics, http://
www.roche.com]). The dish was placed on the stage of a temperature-
controlled microscope. Unless otherwise noted, experiments were
conducted at 37 8C. At each time point during the infection, a series
of images was recorded at several focal planes (3–5 in epiﬂuorescence-
and 10–20 in confocal microscopy) within the cell in order to
determine the number of PV which have released their RNA.
Unless otherwise noted, cells were infected at a low MOI (1 pfu per
cell)ofPV.Fortheviruspreparationsusedintheexperimentsreported
here, this corresponds to about 300–400 of virus particles bound per
cell, a density that allows individual virus particles to be readily
discerned.Intherarecasesinwhichvirusesatcertainregionsofthecell
were too dense, that region was excluded from quantitative analysis. A
ﬁeld of view contained ﬁve to ten cells (depending on the cell type).
For pH-dependence microscopy assays, neutral medium (phenol
red–free DMEM, 1% glucose, oxygen-scavenging system, 50 mM
Hepes [Sigma], pH 7.2) was carefully aspirated and quickly replaced
by basic medium (phenol red–free DMEM, 1% glucose, oxygen-
scavenging system, 50 mM Capso [Sigma], pH 9.5). Immediately after
obtaining the data, the cells were washed with fresh neutral medium.
One pH shift lasted not more than 30 s.
Two-color ﬂuorescence images were collected through a 1.4 N.A.
oil-immersion objective (Olympus, http://www.olympus.co.jp/en/), sep-
arated by 650 nm long-pass dichroic mirrors (Chroma, http://
www.chroma.com), and imaged onto two separate areas of a charge-
coupled device (CCD) camera (CoolSNAP HQ; Roper Scientiﬁc,
http://roperscientiﬁc.com). Capsid signals (Cy5 or CypHer5) were
detected using continuous excitation with 633 nm HeNe laser
(Melles-Griot, http://www.mellesgriot.com), and their signals were
collected through a 665 nm long-pass ﬁlter (Chroma). The Syto82
signals were excited with a 532 nm Nd:YAG laser (Crystalaser, http://
www.crystalaser.com) strobed at 1 Hz. The strobing reduced the laser
illumination time and thus avoided photobleaching of Syto82. It also
allowed the separate analysis of Cy5 (viral capsid) signals without the
cellular background generated at 532 nm and the crosstalk of Syto82.
Syto82 signals were collected through a 585/35 nm bandpass ﬁlter
(Chroma). All images were acquired at 2 Hz for the Cy5 signal and 1
Hz for the Syto82 signal. Differential interference contrast (DIC)
optics (Olympus) was used to obtain cell images before and after the
ﬂuorescence imaging. Experiments were conducted at 378C.
Image analysis. Image analysis was carried out using custom-
written IDL software as previously described [39] (including a Fourier
bandpass ﬁlter and convolution with a Gaussian function, the width
of which was twice the size of the point spread function of the
microscope, both of which reduce background signals and noise).
Colocalization of RNA and viral capsid signals was identiﬁed by an
automated program and conﬁrmed by eye. Objects were scored as
colocalized if the distance between the center of the ﬂuorescence
image of the RNA and the ﬂuorescence image of the capsid was less
than four pixels. To estimate the error in the calculated colocaliza-
tion fraction due to overlap by chance, randomly distributed spots of
each color with the experimentally determined point spread function
were analyzed and resulted in a colocalization fraction of smaller
than 10% due to random overlap.
Drugs and silencing RNA. Working concentrations of the drugs are
notedin parentheses.R78206(10lg/ml)wasa generous giftfromKoen
Andries (Janssen Pharmaceuticals). Nocodazole (10 lg/ml), brefeldin A
(10lg/ml),baﬁlomycinA1(320nM),Cyto-D(10lg/ml),genistein(12.5–
187.5 lg/ml), genistin (8–120 lg/ml), SU6656 (1–30 mM), chlorproma-
zine (0.5–20 lg/ml), ﬁlipin (2–20 lg/ml), sodium azide (20 mM), 2-
deoxyglucose (50 mM), and amiloride (200 lM)were purchased from
Sigma. PP2 (1–20 lM) and wiskostatin (5–20 lM) were purchased from
EMD Biosciences ( http://www.emdbiosciences.com/home.asp). siRNA
for the clathrin heavy chain (CLTC, SMARTpool L-004001-00-0005)
and the l1 subunit of adaptor protein 2 (AP2M1, SMARTpool L-
008170-00-0005) were purchased from Dharmacon (http://www.
dharmacon.com). Flotillin-1 siRNA and control siRNA were obtained
from Santa Cruz Biotechnology (http://www.scbt.com) Cells were
transfectedataﬁnalconcentrationof5nMat2and1daypreinfection.
Neutral red infectious center assay. Monolayers of cells were
pretreated with a drug in serum-free media for 1 h. In the dark, cells
were infected at an MOI equal to one. Virus adsorption was
performed at 12 8C for 30 min in the presence of the drug.
Nonbound virus was rinsed off with cold PBS. Infection was initiated
with the addition of warm, drug-containing medium and continued
at 37 8C. At 30 min p.i., infected monolayers are exposed to white
light (transilluminator; VWR, http://www.vwrsp.com) for 10 min at
room temperature, while duplicate control monolayers are main-
tained in the dark. Cells were then trypsinized and counted. Known
dilutions of the infected cells in drug-free, complete medium were
plated onto new monolayers of cells and allowed to adhere. At 4 h p.i.,
the medium was replaced with an agar overlay. The number of
plaques, each representing an infected cell from the original
monolayer, was counted at 36–48 h p.i.. For cells treated with siRNA,
drugs were omitted in all steps.
Western blot analysis. Western blot analyses were performed as
previously described [55]. CLTC was detected using a 1:1,000 dilution
of mouse anti-CLTC monoclonal antibody (BD Biosciences http://
www.bdbiosciences.com). AP2M1 was detected using a 1:1,000
dilution of mouse anti-AP50 monoclonal antibody (BD Biosciences).
a-Tubulin was detected using a 1:2,000 dilution of mouse anti–a-
tubulin monoclonal antibody (Invitrogen). Flotillin was detected
using a 1:1,000 dilution of a mouse anti-ﬂotillin-1 (H-104) polyclonal
antibody (Santa Cruz Biotechnology).
Supporting Information
Figure S1. Metabolic Labeling of PV RNA with Syto 82 or Neutral Red
Does Not Reduce the Infectivity
White light illumination of NR-labeled, but not of Cy5 or Syto82,
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Polio EntryPV leads to photoinactivation and signiﬁcant reduction of
speciﬁc infectivity.
Found at doi:10.1371/journal.pbio.0050183.sg001 (149 KB TIF).
Figure S2. Time Lapse Images of PV RNA Release
Live HeLa cell were incubated with dual-labeled PV (RNA with
Syto82, green, and capsid with Cy5, red) (MOI ¼ 1) and the RNA
release was observed on a single-particle level in the same cell over
time. The cell boundaries were traced with blue lines, and the nuclei
were marked with ‘‘N.’’
(A) Wide-ﬁeld illumination (epi) of the bottom focal plane of the cell.
(B) To conﬁrm that the disappearance of the RNA signal was not due
to photobleaching, the experiment was conducted at room temper-
ature (24 8C) at which the structural conversion of the capsid (160S to
135S) was signiﬁcantly inhibited. Scale bar indicates 10 lm.
(C) RNA release over time observed in the same cell using TIRF
imaging geometry.
Found at doi:10.1371/journal.pbio.0050183.sg002 (4.5 MB TIF).
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